Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2014

View Archived Issues

Dong Wha licenses natural extracts for IBD from Kyung Hee University

Sanofi reflects on accomplishments of second quarter 2014

Dignity Sciences completes phase I trial of oral DS-107G

Lightlake Therapeutics receives funding for development of intranasal naloxone

Sirona Biochem synthesizes first compound in joint venture with Bloom Burton

Targazyme awarded grant to study treatment of retinopathy using autologous stem cells

GlaxoSmithKline discloses new FAS inhibitors for cancer

Chinese researchers divulge novel coagulation factor Xa inhibitors

Sichuan University divulges novel AChE inhibitors

Sanofi synthesizes novel SEH inhibitors

Development of a novel, potent enzyme inhibitor for the treatment of type 2 diabetes

Scientists at Roche disclose novel OT-R agonists for CNS disorders

GSK and Genmab report interim data for phase III study of ofatumumab in relapsed CLL

Alexza Pharmaceuticals provides pipeline update

TNT-003 inhibits anti-HLA antibody-induced complement deposition in vitro

Genzyme receives label expansion for Lumizyme in the U.S.

Preclinical murine skin allograft model results presented for CD28-specific domain antibody

Shionogi offers overview of first quarter of fiscal 2014

Amarantus reports data for LymPro Test and licenses property from University of Leipzig

Cysteamine bitartrate receives European orphan drug status for Huntington's disease

Medivir licenses RSV drug program from Boehringer Ingelheim

Roche to acquire Santaris Pharma

Laninamivir octanoate misses primary endpoint in phase II influenza trial

FDA grants orphan drug designation to Genoa's inhaled pirfenidone for IPF

U.S. and E.U. orphan drug designations for AbbVie's ABT-414 for glioblastoma multiforme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...